Skip to main content

Table 2 Baseline characteristics of participants

From: Efficacy and safety of oxygen-sparing nasal reservoir cannula for treatment of pediatric hypoxemic pneumonia in Uganda: a pilot randomized clinical trial

 

Entire Cohort (n = 16)

Group Aa

(n = 8)

Group Bb

(n = 8)

Demographics

 Male sex (n, %)

8 (50)

5 (63)

3 (38)

 Age (months), median (IQR)

23 (17–29)

20 (15–28)

26 (20–32)

Past medical history

 Pneumonia

6 (38)

2 (25)

4 (50)

 Asthma

1 (6)

1 (13)

0

 HIV

0

0

0

 Malaria

3 (17)

0

3 (38)

Clinical examination

 Baseline SpO2

90 (88–93)

89 (88–92)

90 (87–93)

  85–89%

8 (50)

4 (50)

4 (50)

  90–94%

8 (50)

4 (50)

4 (50)

Weight (kg), median (IQR)

11.4 (9.0–13.0)

11.5 (9.0–13.1)

10.9 (9.5–12.6)

Temperature (°C), median (IQR)

37.4 (37–37.9)

37.4 (37.1–37.5)

37.9 (37–38.1)

Blood pressure (mmHg)3

 Systolic, median (IQR)

95 (92–101)

96 (87–104)

95 (92–100)

 Diastolic, median (IQR)

67 (62.5–78.5)

65 (60–72)

73 (65–80)

Heart Rate (bpm), median (IQR)

157 (138–168)

152 (142–160)

159 (135–179)

Respiratory rate (bpm), median (IQR)

63 (57.5–76)

66 (60–76)

63 (54–76)

Tachypnea

16 (100)

8 (100)

8 (100)

Delayed Capillary refill time

0

0

0

Absent or unequal breath sounds

0

0

0

Wheeze

1 (8)

0

1 (6)

Crackles

12 (75)

6 (75)

6 (75)

Stridor

0

0

0

Rapid or shallow breathing

16 (100)

8 (100)

8 (100)

Increased work of breathing

16 (100)

8 (100)

8 (100)

Chest wall asymmetry

0

0

0

Consciousness

 Alert

16 (100)

8 (100)

8 (100)

 Response to Voice

0

0

0

 Response to pain

0

0

0

 Unresponsive

0

0

0

SICK scores

2.1 (0.9–2.2)

1.5 (0.9–2.1)

2.1 (1.4–2.3)

Investigations, median (IQR)

 Venous blood gas

  Lactate (mmol/L)

1.8 (1.54–1.9)

1.9 (1.8–2)

1.7 (1.4–2.0)

  pH

7.4 (7.4–7.5)

7.4 (7.4–7.5)

7.5 (7.4–7.5)

  pCO2 (mmHg)

27 (24–32)

27 (25–32)

28 (24–31)

  paO2 (mmHg)

44 (43–47)

43 (42–46)

45 (43–49)

  BE (mmol/L)

-5 (−8 to − 4)

−6 (− 9 to − 5)

−5 (− 6 to − 2)

  HCO3 (mmol/L)

19 (17–20)

18 (16–20)

20 (18–21)

 Blood glucose (mmol/L)

6 (5.2–6.9)

5.6 (5.1–6.5)

6.5 (5.5–7.0)

 Hematologic parameters

  Hemoglobin (g/dL)

11.1 (10–11.8)

11 (10–12.2)

11.1 (10–11.5)

  Hematocrit (%)

35 (31–36)

34 (31–36)

34 (31–36)

  White blood cell count (x103μL)

13 (8–18)

10 (8–21)

15 (7–18)

  Platelet count (×103 μL)

396 (271–552)

424 (320–552)

396 (260–540)

  1. Data represent n (%) unless otherwise specified
  2. IQR Interquartile Range
  3. aGroup A received OSNRC during Period 1, followed by SNC during Period 2
  4. bGroup B received SNC during Period 1, followed by OSNRC during Period 2